Business Context and Reporting Period
BioNTech SE filed a Form 6-K covering March 2024. The filing reports a management appointment announced on March 20, 2024.
Material Corporate Change
- The Supervisory Board appointed Annemarie Hanekamp to BioNTech’s Management Board as Chief Commercial Officer.
- Her appointment is effective July 1, 2024.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, business outlook commentary, risk disclosures, contingencies, or unusual financial items.
Important Facts to Verify
- Verify the effective date of July 1, 2024, and Ms. Hanekamp’s responsibilities as Chief Commercial Officer.
- Review Exhibit 99.1 for the company’s detailed announcement and management background information.